Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00724867 · ClinicalTrials.gov registry record · Phase 3
A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
A Phase 3 study, sponsored by Human Genome Sciences Inc., a GSK Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 268
- Enrollment target
NCT00724867 is a Phase 3 study that has completed, run by Human Genome Sciences Inc., a GSK Company. The registered enrollment target is 268 participants.
The verdict
NCT00724867, a Phase 3 study, has completed, sponsored by Human Genome Sciences Inc., a GSK Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 268 participants
- Enrollment target
Study Summary
This is a continuation study to provide continuing treatment to subjects who completed study HGS1006-C1056 in the United States, to evaluate the long-term safety and efficacy of belimumab(LymphoStat-B™) in subjects with SLE disease.
Interventions
- BIOLOGICAL Belimumab 10 mg/kg
- BIOLOGICAL Belimumab 1 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 268 participants |
| Start Date | 2008-08 |
| Est. Completion | 2015-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00724867
The ClinicalTrials.gov registry entry for NCT00724867 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 268 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Human Genome Sciences Inc., a GSK Company, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Belimumab 10 mg/kg is the first listed.
NCT00724867 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00724867 about?
NCT00724867 is a clinical study titled "A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States". This is a continuation study to provide continuing treatment to subjects who completed study HGS1006-C1056 in the United States, to evaluate the long-term safety and efficacy of belimumab(LymphoStat-B™) in subjects with SLE disease.
What is the current status of trial NCT00724867?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 268 participants. The study started on 2008-08. Estimated completion is 2015-03.
What interventions are being tested in trial NCT00724867?
The interventions under investigation include: Belimumab 10 mg/kg (BIOLOGICAL), Belimumab 1 mg/kg (BIOLOGICAL).
Who is sponsoring clinical trial NCT00724867?
This trial is sponsored by Human Genome Sciences Inc., a GSK Company, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.